Allogene Therapeutics (ALLO) Short Interest Ratio & Short Volume $1.13 -0.04 (-3.42%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Allogene Therapeutics Short Interest DataAllogene Therapeutics (ALLO) has a short interest of 19.94 million shares, representing 10.35% of the float (the number of shares available for trading by the public). This marks a -18.51% decrease in short interest from the previous month. The short interest ratio (days to cover) is 5.1, indicating that it would take 5.1 days of the average trading volume of 4.27 million shares to cover all short positions.Current Short Interest19,940,000 sharesPrevious Short Interest24,470,000 sharesChange Vs. Previous Month-18.51%Dollar Volume Sold Short$22.53 millionShort Interest Ratio5.1 Days to CoverLast Record DateAugust 31, 2025Outstanding Shares221,880,000 sharesShort Percent of Float10.35%Today's Trading Volume1,255,511 sharesAverage Trading Volume4,273,029 sharesToday's Volume Vs. Average29% Short Selling Allogene Therapeutics? Sign up to receive the latest short interest report for Allogene Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Get Report View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartALLO Short Interest Over TimeALLO Days to Cover Over TimeALLO Percentage of Float Shorted Over Time Allogene Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 8/31/202519,940,000 shares $22.53 million -18.5%10.4%5.1 $1.13 8/15/202524,470,000 shares $26.92 million +0.1%N/A6.3 $1.10 7/31/202524,450,000 shares $30.07 million -5.7%12.9%6.2 $1.23 7/15/202525,930,000 shares $32.15 million -2.4%N/A7.8 $1.24 6/30/202526,570,000 shares $30.02 million +2.0%14.0%8.1 $1.13 6/15/202526,040,000 shares $34.89 million +6.0%13.7%8.6 $1.34 5/31/202524,570,000 shares $28.62 million -10.2%15.5%7.4 $1.17 5/15/202527,360,000 shares $29.82 million -9.2%17.2%7.9 $1.09 4/30/202530,130,000 shares $50.62 million -8.2%N/A5.5 $1.68 4/15/202532,810,000 shares $47.90 million -5.6%20.7%6.3 $1.46 Get the Latest News and Ratings for ALLO and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Allogene Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 3/31/202534,760,000 shares $50.75 million -8.6%24.9%6.5 $1.46 3/15/202538,010,000 shares $73.74 million -2.8%27.2%7.1 $1.94 2/28/202539,100,000 shares $76.25 million +16.2%29.1%7.6 $1.95 2/15/202533,660,000 shares $68.67 million +5.0%25.0%6.7 $2.04 1/31/202532,050,000 shares $57.69 million -0.9%22.8%11.7 $1.80 1/15/202532,350,000 shares $60.49 million +4.7%N/A12 $1.87 12/31/202430,910,000 shares $65.84 million -4.5%N/A12.4 $2.13 12/15/202432,370,000 shares $61.18 million +3.9%N/A14.1 $1.89 11/30/202431,170,000 shares $77.30 million -11.1%N/A13.8 $2.48 11/15/202435,050,000 shares $79.56 million -5.4%N/A16.2 $2.27 10/31/202437,040,000 shares $94.64 million -5.8%26.7%18.7 $2.56 10/15/202439,320,000 shares $106.56 million +2.1%28.5%21.7 $2.71 9/30/202438,510,000 shares $107.83 million -1.7%28.2%18.3 $2.80 9/15/202439,190,000 shares $116.00 million +0.6%28.7%17 $2.96 8/31/202438,940,000 shares $102.41 million -0.7%28.5%15.8 $2.63 8/15/202439,230,000 shares $90.23 million +3.9%28.7%14.5 $2.30 7/31/202437,750,000 shares $110.99 million -12.7%27.6%12.9 $2.94 7/15/202443,230,000 shares $128.83 million +4.5%31.6%14.7 $2.98 6/30/202441,380,000 shares $96.42 million -4.4%30.3%15.3 $2.33 6/15/202443,280,000 shares $101.71 million +6.7%31.7%17.1 $2.35 5/31/202440,570,000 shares $101.43 million +11.4%33.5%16.2 $2.50 5/15/202436,430,000 shares $108.56 million +7.6%30.1%15.7 $2.98 4/30/202433,870,000 shares $93.48 million +8.0%32.0%15.5 $2.76 4/15/202431,360,000 shares $111.33 million +2.4%30.0%13.9 $3.55 3/31/202430,620,000 shares $136.87 million +10.3%29.3%11.7 $4.47 3/15/202427,750,000 shares $129.32 million +11.0%26.6%10 $4.66 2/29/202425,010,000 shares $122.80 million +6.7%24.1%8.3 $4.91 2/15/202423,450,000 shares $116.31 million +1.6%22.6%7.7 $4.96 1/31/202423,090,000 shares $81.28 million -23.6%22.2%7.4 $3.52 1/15/202430,210,000 shares $97.28 million -3.5%28.5%10.3 $3.22 12/31/202331,320,000 shares $100.54 million -6.7%29.6%11.9 $3.21 12/15/202333,550,000 shares $90.92 million +5.3%31.7%14.3 $2.71 11/30/202331,860,000 shares $74.87 million -1.5%30.1%16.8 $2.35 11/15/202332,340,000 shares $87.96 million -5.0%30.6%18.9 $2.72 10/31/202334,030,000 shares $95.96 million +10.7%32.2%22 $2.82 10/15/202330,730,000 shares $98.03 million -10.0%29.2%18 $3.19 9/30/202334,130,000 shares $108.19 million +2.1%32.2%19 $3.17 9/15/202333,420,000 shares $130.00 million +4.1%31.5%16.2 $3.89 8/31/202332,110,000 shares $124.91 million -2.0%30.3%12.4 $3.89 8/15/202332,770,000 shares $133.70 million -13.6%30.9%12.5 $4.08 7/31/202337,910,000 shares $188.03 million -8.1%39.4%14.3 $4.96 7/15/202341,260,000 shares $204.65 million +8.1%53.9%15.3 $4.96 6/30/202338,180,000 shares $189.75 million +1.7%49.9%14.1 $4.97 6/15/202337,560,000 shares $186.67 million -6.2%49.1%15.1 $4.97 5/31/202340,030,000 shares $210.16 million -1.4%52.1%20.4 $5.25 5/15/202340,590,000 shares $273.58 million -0.2%52.8%19.6 $6.74 4/30/202340,650,000 shares $220.73 million -1.4%53.3%20.3 $5.43 4/15/202341,220,000 shares $205.69 million +0.5%54.5%22.2 $4.99 3/31/202341,010,000 shares $202.59 million +3.0%54.3%22.5 $4.94 3/15/202339,800,000 shares $225.27 million +8.0%49.6%20.9 $5.66 2/28/202336,860,000 shares $234.06 million +4.9%46.0%19.4 $6.35 2/15/202335,140,000 shares $254.06 million +2.1%44.0%18.4 $7.23 1/31/202334,410,000 shares $265.65 million +0.7%43.1%18 $7.72 1/15/202334,160,000 shares $241.17 million +2.2%42.7%18.1 $7.06 12/30/202233,430,000 shares $210.27 million +9.5%41.8%18 $6.29 12/15/202230,530,000 shares $216.15 million +0.2%38.2%16 $7.08 11/30/202230,470,000 shares $300.43 million -3.2%38.1%16.5 $9.86 11/15/202231,460,000 shares $311.45 million +1.6%39.3%18.2 $9.90 10/31/202230,960,000 shares $318.89 million +3.0%39.3%18.3 $10.30 10/15/202230,050,000 shares $305.91 million +8.9%38.3%18 $10.18 9/30/202227,590,000 shares $297.97 million +24.2%35.2%16 $10.80 9/15/202222,220,000 shares $311.08 million +0.9%28.3%12.8 $14.00 8/31/202222,020,000 shares $301.89 million -2.4%28.1%12 $13.71 8/15/202222,570,000 shares $390.01 million +0.8%28.8%11.6 $17.28 7/31/202222,400,000 shares $290.75 million -0.1%28.6%10.9 $12.98 7/15/202222,430,000 shares $287.33 million -0.3%28.6%10.2 $12.81 6/30/202222,490,000 shares $256.39 million +2.0%28.5%10.5 $11.40 6/15/202222,060,000 shares $212.22 million +9.5%28.0%10.8 $9.62 5/31/202220,150,000 shares $159.79 million +13.9%25.7%10.8 $7.93 5/15/202217,690,000 shares $127.90 million -0.4%22.5%9.6 $7.23 4/30/202217,760,000 shares $148.30 million -1.7%24.3%10.4 $8.35 4/15/202218,060,000 shares $149.00 million +18.6%24.8%11.4 $8.25 3/31/202215,230,000 shares $138.75 million +4.8%16.1%8.9 $9.11 3/15/202214,540,000 shares $113.41 million +18.7%19.8%8.6 $7.80 2/28/202212,250,000 shares $112.09 million +16.9%16.7%7.5 $9.15 2/15/202210,480,000 shares $106.79 million +10.0%14.3%6.8 $10.19 1/31/20229,530,000 shares $109.12 million +5.1%14.3%6.6 $11.45 1/15/20229,070,000 shares $120.45 million +19.7%13.6%6.2 $13.28 12/31/20217,580,000 shares $113.09 million +34.9%11.4%4.1 $14.92 12/15/20215,620,000 shares $86.38 million +4.7%8.4%2.7 $15.37 11/30/20215,370,000 shares $99.29 million -5.3%8.1%2.9 $18.49 11/15/20215,670,000 shares $106.99 million +19.6%8.5%3.1 $18.87 10/29/20214,740,000 shares $81.72 million +0.2%7.1%2.6 $17.24 10/15/20214,730,000 shares $77.95 million -40.7%7.1%2.8 $16.48 9/30/20217,980,000 shares $205.09 million +1.7%12.0%6.7 $25.70 9/15/20217,850,000 shares $196.25 million -6.0%11.8%9.5 $25.00 8/31/20218,350,000 shares $199.15 million -0.4%11.7%9.4 $23.85 8/13/20218,380,000 shares $179.67 million -9.6%11.7%7.5 $21.44 7/30/20219,270,000 shares $203.48 million -2.2%13.0%7.1 $21.95 7/15/20219,480,000 shares $211.88 million +0.2%13.3%7.1 $22.35 6/30/20219,460,000 shares $246.72 million +15.5%13.3%7 $26.08 6/15/20218,190,000 shares $205.00 million +3.0%11.5%7 $25.03 5/28/20217,950,000 shares $204.32 million -3.4%11.3%6.8 $25.70 5/14/20218,230,000 shares $221.72 million +13.5%11.6%7.8 $26.94 4/30/20217,250,000 shares $231.86 million -12.7%10.2%8.5 $31.98 4/15/20218,300,000 shares $266.85 million -3.8%11.9%10.1 $32.15 3/31/20218,630,000 shares $288.50 million -16.1%12.4%10 $33.43 3/15/202110,290,000 shares $395.96 million -10.9%14.6%11.1 $38.48 2/26/202111,550,000 shares $378.72 million +4.2%16.5%12.4 $32.79 2/12/202111,080,000 shares $381.15 million -4.0%15.8%12.6 $34.40 1/29/202111,540,000 shares $398.25 million -15.9%16.8%12.8 $34.51 1/15/202113,720,000 shares $426.28 million +5.2%20.1%14.8 $31.07 12/31/202013,040,000 shares $347.39 million +15.7%19.1%15.4 $26.64 12/15/202011,270,000 shares $315.56 million +5.8%16.5%13.8 $28.00 11/30/202010,650,000 shares $335.69 million +0.7%15.7%14.1 $31.52 11/15/202010,580,000 shares $339.30 million +5.1%15.6%15.4 $32.07 10/30/202010,070,000 shares $358.19 million -0.5%14.9%15.5 $35.57 10/15/202010,120,000 shares $436.88 million -2.3%15.0%17.2 $43.17 9/30/202010,360,000 shares $390.68 million +1.5%15.4%17.7 $37.71 9/15/202010,210,000 shares $363.58 million -5.0%15.1%16.3 $35.61 ALLO Short Interest - Frequently Asked Questions What is Allogene Therapeutics' current short interest? Short interest is the volume of Allogene Therapeutics shares that have been sold short but have not yet been covered or closed out. As of August 31st, investors have sold 19,940,000 shares of ALLO short. 10.35% of Allogene Therapeutics' shares are currently sold short. Learn More on Allogene Therapeutics' current short interest. What is a good short interest ratio for Allogene Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ALLO shares currently have a short interest ratio of 5.0. Learn More on Allogene Therapeutics's short interest ratio. Which institutional investors are shorting Allogene Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Allogene Therapeutics: Group One Trading LLC, and Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Allogene Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 10.35% of Allogene Therapeutics' floating shares are currently sold short. Is Allogene Therapeutics' short interest increasing or decreasing? Allogene Therapeutics saw a drop in short interest during the month of August. As of August 31st, there was short interest totaling 19,940,000 shares, a drop of 18.5% from the previous total of 24,470,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Allogene Therapeutics' short interest compare to its competitors? 10.35% of Allogene Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Allogene Therapeutics: ARS Pharmaceuticals, Inc. (36.05%), Praxis Precision Medicines, Inc. (11.94%), uniQure N.V. (17.34%), atai Life Sciences N.V. (12.59%), Cronos Group Inc. (1.31%), CorMedix Inc (16.82%), Taysha Gene Therapies, Inc. (15.54%), Immunome, Inc. (17.09%), Amylyx Pharmaceuticals, Inc. (12.64%), Iovance Biotherapeutics, Inc. (24.37%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($73.23 billion), Invesco QQQ ($29.52 billion), iShares Russell 2000 ETF ($20.82 billion), iShares 20+ Year Treasury Bond ETF ($10.76 billion), Palo Alto Networks, Inc. ($9.37 billion), Strategy Inc ($7.58 billion), Invesco S&P 500 Equal Weight ETF ($6.78 billion), SPDR S&P Biotech ETF ($6.72 billion), AppLovin Corporation ($6.37 billion), and iShares iBoxx $ Investment Grade Corporate Bond ETF ($6.29 billion). View all of the most shorted stocks. What does it mean to sell short Allogene Therapeutics stock? Short selling ALLO is an investing strategy that aims to generate trading profit from Allogene Therapeutics as its price is falling. ALLO shares are trading up $0.06 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Allogene Therapeutics? A short squeeze for Allogene Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of ALLO, which in turn drives the price of the stock up even further. How often is Allogene Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ALLO, twice per month. The most recent reporting period available is August, 31 2025. More Short Interest Resources from MarketBeat Related Companies ARS Pharmaceuticals Short Squeeze Praxis Precision Medicines Short Squeeze uniQure Short Squeeze atai Life Sciences Short Squeeze Cronos Group Short Squeeze CorMedix Short Squeeze Taysha Gene Therapies Short Squeeze Immunome Short Squeeze Amylyx Pharmaceuticals Short Squeeze Iovance Biotherapeutics Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:ALLO) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredGENIUS Act: The Plot to Seize Your Cash?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe $17B signal no one expected…After SpaceX struck a $17 billion deal with EchoStar for a block of radio frequencies, tech analyst Jeff Brown...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allogene Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Allogene Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALLO Stock Alerts